Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
3 min read Senior Vice President, Operations (Photo: Business Wire) President and CEO (Photo: Business Wire) Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence BRIDGEWATER, N.J., February 10, 2025 BUSINESS WIRE )--Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. "As we rapidly diversify our product portfolio and expand our footprint, we continue to enhance our operational capabilities" said Apurva Saraf, President and CEO, Cosette Pharmaceuticals. "Vin is an exceptional leader with deep expertise in leading complex operations with high-performing team
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid MalignanciesBusiness Wire
- ValGenesis Wraps Up Global ValConnect Innovation Day Series with Hyderabad Event [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Dr. Reddy's Laboratories (NYSE:RDY) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025Business Wire
RDY
Earnings
- 7/24/25 - Beat
RDY
Sec Filings
- 12/16/25 - Form 6-K
- 12/16/25 - Form 6-K
- 12/12/25 - Form 6-K
- RDY's page on the SEC website